



Contents lists available at ScienceDirect

EBioMedicine

journal homepage: [www.ebiomedicine.com](http://www.ebiomedicine.com)
**EBioMedicine**  
 Published by THE LANCET

## Mitochondrial enzyme GLUD2 plays a critical role in glioblastoma progression

Sara Franceschi<sup>a,\*</sup>, Debora Corsinovi<sup>b,c,1</sup>, Francesca Lessi<sup>a</sup>, Elena Tantillo<sup>a</sup>, Paolo Aretini<sup>a</sup>, Michele Menicagli<sup>a</sup>, Claudia Scopelliti<sup>a</sup>, Prospero Civita<sup>a</sup>, Francesco Pasqualetti<sup>d</sup>, Antonio G. Naccarato<sup>b</sup>, Michela Ori<sup>c,\*</sup>, Chiara M. Mazzanti<sup>a,1</sup>

<sup>a</sup> Fondazione Pisana per la Scienza ONLUS, Pisa, Italy

<sup>b</sup> Department of Translational Research and of New Surgical and Medical Technologies, University Hospital of Pisa, Pisa, Italy

<sup>c</sup> Department of Biology, University of Pisa, Pisa, Italy

<sup>d</sup> Radiotherapy Department, University Hospital of Pisa, Pisa, Italy

### ARTICLE INFO

#### Article history:

Received 28 August 2018

Received in revised form 25 September 2018

Accepted 2 October 2018

Available online xxx

#### Keywords:

Glioblastoma

GLUD2

Glutamate

Mitochondrial metabolism

Tumor progression

Zebrafish

### ABSTRACT

**Background:** Glioblastoma (GBM) is the most frequent and malignant primary brain tumor in adults and despite the progress in surgical procedures and therapy options, the overall survival remains very poor. Glutamate and  $\alpha$ -KG are fundamental elements necessary to support the growth and proliferation of GBM cells. Glutamate oxidative deamination, catalyzed by GLUD2, is the predominant pathway for the production of  $\alpha$ -KG.

**Methods:** GLUD2 emerged from the RNA-seq analysis of 13 GBM patients, performed in our laboratory and a microarray analysis of 77 high-grade gliomas available on the Geo database. Thereafter, we investigated GLUD2 relevance in cancer cell behavior by GLUD2 overexpression and silencing in two different human GBM cell lines. Finally, we overexpressed *GLUD2 in-vivo* by using zebrafish embryos and monitored the developing central nervous system.

**Findings:** GLUD2 expression was found associated to the histopathological classification, prognosis and survival of GBM patients. Moreover, through *in-vitro* functional studies, we showed that differences in GLUD2 expression level affected cell proliferation, migration, invasion, colony formation abilities, cell cycle phases, mitochondrial function and ROS production. In support of these findings, we also demonstrated, with *in-vivo* studies, that *GLUD2* overexpression affects glial cell proliferation without affecting neuronal development in zebrafish embryos.

**Interpretation:** We concluded that GLUD2 overexpression inhibited GBM cell growth suggesting a novel potential drug target for control of GBM progression. The possibility to enhance GLUD2 activity in GBM could result in a blocked/reduced proliferation of GBM cells without affecting the survival of the surrounding neurons.

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### 1. Introduction

Glioblastoma (GBM, World Health Organization grade IV) is the most common malignant primary brain tumor, characterized by an extremely aggressive clinical phenotype due to inter- and intra-patient genomic and histopathological diversity, diffuse infiltrative growth, intense vascularization and innate treatment resistance [1–6]. Despite significant advances in both neurosurgical techniques and medical therapy, GBM treatment remains difficult, as present-days therapies

are not curative and the latest improvements in radio-chemotherapy have been reported by Stupp et al. [7] >10 years ago [2,8].

GBM prognosis is extremely poor with a median overall survival between 12 and 15 months and a 5-year survival rate of <5%, making this survival rate one of the worst observed in modern-day oncology [1,2,5]. Almost all patients, under current standard therapy, including maximal safe surgical resection followed by radiotherapy and temozolomide chemotherapy, will develop recurrent diseases with progressive neurological deficits and inevitable death. Second surgery is an applicable therapy option in limited cases; however, an increased risk of neurological morbidity often limits this secondary resection [9].

Unlike in other tumors, where in the past 50 years, the prognosis and life expectancy have strongly increased due to intensive research efforts into tumor cell biology, in GBM, such investigations, have raised more doubts than they have solved [3]. Therefore, there is still an urgent

\* Corresponding authors.

E-mail addresses: [s.franceschi@fpscience.it](mailto:s.franceschi@fpscience.it) (S. Franceschi), [michela.ori@unipi.it](mailto:michela.ori@unipi.it) (M. Ori).

<sup>1</sup> These authors contributed equally to this work.

## Research in context

### Evidence before this study

The involvement of GLUD2 in glioma metabolism and growth has already been suggested, but only in the presence of IDH1 mutations (Cancer Res, 2018 and Proc Natl Acad Sci U S A, 2014). It has been described that GLUD1 and GLUD2 are overexpressed in IDH1 mutant tumors. In this context, the expression of GLUD2 makes cells resistant to the inhibitory effects of growth of the IDH1R132H mutation, by providing  $\alpha$ -KG to feed the citric acid cycle and support the synthesis of lipids. In other studies, instead, it was investigated the inhibition of glutamate dehydrogenase activity in glioma, without distinguishing the two existing isoforms GLUD1 and GLUD2 (Cancer Res, 2009). To the best of our knowledge, this is the first work where GLUD2 is investigated as a key player in GBM progression. The research in PubMed database, according to the terms “GLUD2” or “GDH2” and “glioblastoma”, does not provide any other results except for the work, previously mentioned, that was published on Proc Natl Acad Sci U S A in 2014.

### Added value of this study

In this study we found an association of GLUD2 mRNA expression levels to the prognosis and survival of patients with GBM. Thereafter, through *in-vitro* functional studies using human GBM cell lines and *in-vivo* studies in zebrafish model, we investigated the importance of GLUD2 regulation in cell behavior, metabolism and development. GLUD2 expression was related to the histopathological classification, prognosis and survival of patients with GBM. Moreover, differences in GLUD2 expression level affected cell proliferation, migration, invasion, colony formation abilities, cell cycle phases, mitochondrial function and ROS production. In support of these findings, we also demonstrated that GLUD2 overexpression decreases glial cell proliferation without affecting neurons development in zebrafish embryos.

### Implications of all the available evidence

The possibility to enhance GLUD2 activity in GBM could result in a blocked/reduced proliferation of GBM cells without affecting the survival of the surrounding neurons. To the best of our knowledge, this is the first work where GLUD2 is considered the key player in GBM progression. These observations may provide a new target for therapeutic interventions in GBM to reduce tumor progression and aggressiveness.

need for novel and effective therapeutic strategies for treating these tumors and ultimately improve GBM patients' chances of survival.

One of the emerging hallmarks of cancer is the deregulation of cellular energetics and the most significant reprogramming occurs in the metabolic machinery in GBM [1,10,11]. Thus, cancer cell metabolism is now a field of intensive investigation to discover new valuable therapeutic targets and biomarkers [10]. In particular, it is well known that glutamine metabolism plays key roles in cellular growth and invasion, supporting tumor progression and poor patient outcomes [12]. The initial step in glutamine degradation involves its conversion into glutamate catalyzed by glutaminase and the conversion of glutamate into  $\alpha$ -ketoglutarate ( $\alpha$ -KG), by glutamate dehydrogenase. Especially in tumor hypoxia condition, glutamate and  $\alpha$ -KG are fundamental elements in glutaminolysis and reductive carboxylation, needed to sustain cancer cell growth and proliferation. Moreover, glutamate release can

affect nearby cells, since high glutamate levels induce astrocyte swelling and apoptosis, favoring tumor expansion [13]. Furthermore, an efficient excitatory amino acids clearance from astrocytes is essential in order to maintain low extracellular glutamate concentrations and guarantee an adequate regulation of synaptic transmission and prevents glutamate neurotoxicity [14].

Glutamate dehydrogenase 2 (GLUD2) catalyzes the reversible interconversion of glutamate to  $\alpha$ -KG and ammonia while reducing NAD(P)<sup>+</sup> to NAD(P)H as cofactors. This enzyme plays a key role in cellular homeostasis, being at the interface between amino acid and carbohydrate metabolism. GLUD2 is linked to important cellular processes including Krebs cycle, ammonia control and energy generation [15,16].

In this study, we investigated the correlation of GLUD2 expression to patients' prognosis and survival. We investigated, through *in-vitro* and *in-vivo* functional studies, how an alteration of GLUD2 expression could affect the behavior of human glioblastoma cells. Furthermore, we evaluated the effect of GLUD2 expression on the behavior of neurons and glial cells in the zebrafish developing brain.

## 2. Materials and methods

### 2.1. Transcriptome analysis

NGS and microarray analysis data were obtained from our previous paper [17] and the Gene Expression Omnibus (GEO) GSE4271 dataset [18] respectively, together with molecular and clinical information. In particular, NGS analysis was performed on FFPE tumor tissues from 13 primary human GBM subjects selected from the archives of the Anatomy Pathology Institute of the University of Pisa, Italy. Subjects were chosen by the same pathologist, they have same histology, similar condition and treatment and were grouped depending on time of recurrence free survival (RFS) after first surgery: 6 Short (S) <6 months, 3 Medium (M) between 16 and 23 months and 4 Long (L) over 25 months. NGS data were analyzed and visualized with Partek Flow software (Partek, Inc., St. Louis, MO, USA). Microarray GSE4271 profile was downloaded from GEO database (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4271>). GSE4271 contains the mRNA profile of 77 primary grade III and IV astrocytomas characterized by molecular class (proneural, proliferative and mesenchymal) [18] and overall survival.

### 2.2. Immunohistochemistry

#### 2.2.1. Immunohistochemistry performed on FFPE GBM tissues

Sections of 5  $\mu$ m thickness were deparaffinized in xylene and rehydrated in graded alcohols. Immunohistochemistry was performed using the Mouse specific HRP/DAB (ABC) Detection IHC Kit (Abcam, Cambridge, UK) according to manufacturer's protocol. The antigen unmasking was achieved with MS-unmasker solution (DIAPATH, Martinengo, BG, Italy) in microwave. GLUD2 primary antibody (cat. number SAB1400112, Sigma Aldrich, St Louis, MO) was used at 1:150 dilution for 1 h at room temperature. Slides were developed with diaminobenzidine chromogen (DAB) (DAKO, Glostrup, DK) and counterstained with hematoxylin. Negative controls included the omission of the primary antibody. Slides were analyzed using the inverted microscope CARL ZEISS Axio Observer Z1FLMot, and images were taken with CARL ZEISS AXIOCAM Icc1 camera (Zeiss, Oberkochen, Germany).

#### 2.2.2. Immunohistochemistry performed on embryos

Immunohistochemistry was performed following standard procedures. Embryos were blocked in 20% lamb serum and incubated with mouse GLUD2 antibody (1:250 dilution, cat. number SAB1400112, Sigma Aldrich), mouse HuC/D antibody (1:500, cat. number A-21271, Invitrogen), or rabbit phospho-histone H3 antibody (1:500, cat. number 06-570, Millipore). Horseradish peroxidase-conjugated secondary antibodies goat anti-mouse (1:500, cat. number G21040, Invitrogen), or

goat anti-rabbit (1:500, cat. number G21234, Invitrogen) were used to detect primary antibodies, and DAB (Roche) was used as a substrate for peroxidase. Images of embryos were acquired using a stereomicroscope (SMZ1500, Nikon) equipped with digital camera with LAS Leica Imaging software (Leica, Wetzlar, Germany). Images were processed using Adobe Photoshop software (Adobe System Incorporated, San José, CA, USA). The same magnification was always maintained within each control and *GLUD2*-injected image pair.

### 2.3. Cell lines and transfection

T98G and U118 GBM cell lines were obtained from American Type Culture Collection (ATCC, Rockville, MD). To ensure the quality and integrity of human cell lines, cells from the initial thawed vials were used for up to a maximum of 10 passages in all the experiments, as recommended by the supplier. T98G and U118 were grown as monolayers in Dulbecco's Modified Eagle Medium (DMEM) low glucose and high glucose respectively, supplemented with 10% FBS and 1% Penicillin-Streptomycin. Cells were tested for the presence of mycoplasma (EZ-PCR Mycoplasma Test Kit; Biological Industries, Beth Haemek, Israel) with negative results. Amplification of *GLUD2* gene was performed by PCR with the 5' end primer (5'-TAAActcgagGACCCCTCCTCCTAGTCGC-3') containing *XhoI*-site and with the 3' end primer (5'-CGgagtcTCAGCCATGATCCATCTATGTGA-3') containing *BamHI*-site. PCR product was subcloned into pIRES2-AcGFP vector (Clontech Laboratories, Mountain View, CA, USA). *GLUD2* sequence was confirmed by Sanger sequencing. Plasmid transfection was performed with Lipofectamine 3000 Reagent, following manufacturer's instructions. *GLUD2* was silenced using *GLUD2* siRNA Silencer Select (Thermo Fisher Scientific) and the Silencer Select Negative Control No. 1 siRNA was used as non-targeting negative control siRNA (Thermo Fisher Scientific). siRNA transfection was performed with Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific) following manufacturer's instructions. Cells were incubated for 48 h after *GLUD2* overexpression/silencing prior to characterization and functional experiments.

### 2.4. Quantitative real-time PCR

#### 2.4.1. Cell lines mRNA expression analysis

Total cellular RNA was extracted from GBM cells using the Maxwell 16 LEV simplyRNA kit (Madison, WI) according to the manufacturer's instructions, and quantitated using a Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA). Total RNA was reverse transcribed into cDNA using the RT-NanoScript kit (PrimerDesign, Southampton, UK). Real Time PCR was performed following the manufacturer's instruction of the SsoAdvanced SYBR Green Supermix kit (Bio-Rad, Hercules, CA) on CFX96 instrument (Bio-Rad). *TBP* expression values were used for normalization. The following primers were used: *GLUD2*, 5'-CACTCTGCCTGGCATAAC-3' and 5'-CTCAGGTCCAATCCAGGTT-3', *TBP*, 5'-AGTTCTGGGATTGTACCGCA-3', 5'-TTATATTCGGCGTTTCGGGC-3', *Cyclin E*, 5'-TTCTTGAGCAACACCCTCTTTCGAGCC-3' and 5'-TCGCCA TATACCGGTCAAAGAAATCTTGTGCC-3', *Cyclin D1*, 5'-ACAAACAGATC ATCCGAAACAC-3', 5'-TGTTGGGGCTCCTCAGGTTTC-3'. Gene expression analysis was performed using CFX Manager Software (Bio-Rad). All expression experiments were performed in triplicate.

#### 2.4.2. Embryos mRNA expression analysis

Total RNA was extracted from zebrafish embryos (30 per experimental group) using Nucleospin® RNA (Macherey-Nagel) according to manufacturer's instructions. cDNA was synthesized from total RNA using iScript™ cDNA Synthesis Kit (Bio-Rad) and quantitative real-time PCR was performed following the manufacturer's protocol of GoTaq® qPCR master mix (Promega). Ct values were obtained for each gene and normalized to  $\beta$ -actin. Fold change was calculated relative to control embryos expression level using the  $2^{-\Delta\Delta Ct}$  method. The following primers were used: *pna* (F: 5'-TCGGGTGAGTTTGCCCGCA

TC-3'; R: 5'-GCCAGCTCTCCGCTGGCAGA-3'), *cyclin D1* (F: 5'-CTGCGG AACACAGCCCCAGAC-3'; R: 5'-TACCGCTGCAGCAACTGCC-3'), *gfap* (F: 5'-GCAGACAGGTGGATGGACTCA-3'; R: 5'-GGCCAAGTTGTCTCTCTCG ATC-3'),  $\beta$ -actin (F: 5'-CGAGCAGGAGATGGGAACC-3'; R: 5'-CAACGG AACGCTCATTGCC-3').

### 2.5. Western blot

For each samples 40  $\mu$ g of proteins were loaded on the 10% Mini-PROTEAN TGX Gel (Bio-Rad). Proteins were transferred from gels to membrane with Trans-Blot Turbo transfer system (Bio-Rad). *GLUD2* and  $\beta$ -tubulin primary antibodies (HPA043640, Sigma Aldrich) were used at 1:250 and 1:200 dilution respectively. Secondary antibodies Goat Anti-Mouse IgG H&L (HRP) (ab6789, Abcam, Cambridge, UK) and Goat Anti-Rabbit IgG H&L (HRP) (ab6721, Abcam) were used at a dilution of 1:2000. Protein detection was performed using the Bio-Rad Clarity western ECL substrate (Bio-Rad). The ChemiDoc MP imager and Image Lab software (Bio-Rad) were used to validate western blotting data via total protein normalization in conjunction with housekeeping proteins ( $\beta$ -tubulin).

### 2.6. Immunofluorescence

Cells were grown on cell culture chamber slides, and fixed in 1.5% paraformaldehyde for 15 min. Cells were permeabilized with 0.1% Triton X-100 for 15 min and blocked with 2% BSA for 45 min. *GLUD2* primary antibody was diluted 1:250 and incubated for 60 min at RT. Phycoerythrin conjugated secondary antibody (P9287, Sigma Aldrich) was diluted 1:20 and incubated for 30 min. Cells were counterstained with Hoechst (Thermo Fisher Scientific) and visualized using the inverted microscope CARL ZEISS Axio Observer 3 Z1FLMot (Zeiss).

### 2.7. Glutamate dehydrogenase activity

Intracellular glutamate dehydrogenase activity was measured by using the GDH Activity Assay Kit (Sigma-Aldrich) according to the manufacturer's protocol. The activity of glutamate dehydrogenase was assayed photometrically (absorbance at 450 nm) following glutamate consumption by GDH generating NADH, which reacts with a probe generating a colorimetric product proportional to the GDH activity present. After the addition of the Master Reaction Mix the plate was incubated for 3 min at 37 °C degrees and the first measurement was taken. Then, every 10 min the absorbance at 450 nm was measured up to 60 min. The results were visualized as generated NADH nanomoles per minutes, normalized on the total protein concentration of each sample (Bradford Reagent assay, Sigma-Aldrich). The experiment was performed in triplicate.

### 2.8. Cell viability assay

Cell viability was determined using the WST1 assay (Clontech Laboratories, Mountain View, CA, USA). A total of 5000 cells per well were seeded in a 96-well plate format. At the time of seeding (T0) and after 24 h (T1), 48 h (T2) and 72 h (T3), the WST1 reagent was added and incubated for a further 60 min before reading the plate. Each assay was conducted in triplicate. The quantity of formazan dye is directly related to the number of metabolically active cells, and was quantified by measuring the absorbance at 450 nm in a multiwell plate reader (Tecan, Mannedorf, Switzerland). OD values at 24 h (T1), 48 h (T2) and 72 h (T3) were normalized to T0.

### 2.9. Clonogenic survival assay

Cells were seeded at 500 cells/well in 6-well plates and incubated for 2 weeks. Cells were fixed with 70% ethanol and stained with 0.01% crystal violet for 30 min. The mean  $\pm$  SD number of colonies with  $>50 \mu$ m in

diameter was counted under a microscope in five non-overlapping fields in three independent experiments.

### 2.10. Wound healing assay

Cells were plated in Culture-Insert 2 Well in  $\mu$ -Dish 35 mm (IBIDI, Martinsried, Germany) until cells were confluent or nearly confluent (>90%). After the removal of the insert, cell migration in the wound area was observed and digitally photographed. Wound healing was measured on the images by using the free, open-source software ImageJ [36] and the % of closure was calculated at each time (T0–T3, 0–72 h) as the area to be healed divided the area of the original wound \* 100. Relative invasion ability of pIRES-GLUD2 and pIRES Vector transfected cells was measured by counting GFP signal (transfected cells) into the wound. Experiments were performed in triplicate.

### 2.11. Transwell assay

Cell invasion was assessed using 24-well inserts (Sarstedt, Nuembrecht, Germany) with 5- $\mu$ m pores according to manufacturer's instructions. In brief,  $1 \times 10^5$  cells were seeded into the upper chamber with 1% FBS medium and were allowed to invade the lower reservoir, containing 10% FBS, at 37 °C for 24 h. Non-invading cells in the upper surface of the filters were removed using a cotton swab. The remaining cells were fixed in 70% ethanol and stained with 0.01% crystal violet for 30 min. Cells that passed through the membrane were counted in five visual fields as migrated cells. The experiment was performed in triplicate.

### 2.12. Cell-cycle analysis

Approximately  $1 \times 10^6$  cells were fixed in 70% ethanol for 30 min at 4 °C. The cells were then labeled with 25  $\mu$ g/ml of propidium iodide (Sigma Aldrich), 1 mg/ml RNase A (Sigma Aldrich), 0.1% v/v of Triton X-100 (Sigma Aldrich) and incubated 30 min in the dark at 4 °C. The percentage of cells in different phases of the cell cycle was measured by flow cytometry using CyFlow1 Cube 8 Sorter Flow Cytometer (Sysmex Partec, Gortitz, Germany). Data analysis was performed using FCS express 4 software (BD Bioscience San Jose, CA). The experiment was performed in triplicate.

### 2.13. Mitochondrial respiration and glycolysis analysis

Cell mitochondrial function was evaluated by using the Seahorse XFp Cell Mito Stress Test Kit on the Seahorse XFp Analyzer (Agilent Technologies, Santa Clara, CA). Cells were seeded at 20,000 cells per well into XFp well cell culture plates and incubated overnight at 37 °C in a 5% CO<sub>2</sub> humidified atmosphere in Seahorse XF Base Medium (Agilent Technologies) with 1 mM pyruvate, 2 mM glutamine, and 10 mM glucose. Cartridge compounds were loaded in order to have as final concentration 1  $\mu$ M Oligomycin, 1  $\mu$ M FCCP and 0.5  $\mu$ M Rotenone/antimycin A. Data were analyzed and visualized using Wave 2.3.0 software (Agilent Technologies) and values of OCR and ECAR were normalized to the total protein levels (Bradford Reagent assay, Sigma-Aldrich) in each well. The experiment was performed in three replicates.

### 2.14. Oxidative stress

To assess oxidative stress/reactive oxygen species (ROS), cells were transfected with *GLUD2* overexpression vector and silencing siRNA and relative controls for two days in a 96 well plate. CellROX Green reagent was added at final concentration of 5  $\mu$ M to the cells and incubated for 30 min at 37 °C. Medium was removed and cells were washed three times with PBS. The quantity of oxidative stress was quantified by measuring the fluorescence at an excitation/emission wavelength of 485/535 nm in a multiwell plate reader (Tecan). The experiment was

performed in three replicates and fluorescence in each well was measured in four multiple reads.

### 2.15. Zebrafish husbandry

*Danio rerio* (AB strain) was raised and bred at a temperature of 28 °C with a photoperiod of 14 h light/10 h dark. Animal care was performed in strict accordance with protocols approved by the Italian Ministry of Public Health and the University of Pisa Ethical Committee (authorization 99/2012-A, 19.04.2012), in compliance with EU legislation (Directive 2010/63/EU). Zebrafish embryos were obtained by natural spawning, staged according to the hours post fertilization [37] and raised at 28 °C in 1 $\times$  E3 medium (5.0 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl<sub>2</sub>, 0.33 mM MgSO<sub>4</sub>, 0.1% methylene blue) in Petri dishes.

### 2.16. Zebrafish embryos experimental plan

To determine the zebrafish embryos number to analyze in each experimental replicate we followed the indication reported in Busquet et al., 2014 [38]. The authors reported zebrafish embryo experiments results replicated in at least 3 independent laboratories suggesting that the use of 20 embryos per treatment should be maintained to ensure the accuracy of the experimental test. In our experiments, we processed 20–30 embryos per experimental group. Only properly developing embryos between the 4- and 128-cell stages with an intact chorion were used in our experiments as suggested in Busquet et al., 2014 [38].

### 2.17. Constructs generation and RNA microinjection

The open reading frame of *GLUD2* was subcloned into PCS2+ vector. Capped mRNA encoding the full coding sequence of *GLUD2* was synthesized using mMACHINE™ SP6 transcription kit (Thermo Fisher Scientific), following manufacturer's instructions. DNase treatment to remove template DNA was followed by phenol/chloroform extraction and isopropanol precipitation, according to the kit procedures.

A capped mRNA encoding the full coding sequence of an enhanced green fluorescent protein (eGFP) reporter was also produced as described above.

To perform gene gain of function experiments, *GLUD2* capped mRNA was injected into the yolk sac of one-cell stage embryos (~200 pg per embryo). 200 pg of eGFP capped RNA were co-injected to verify successful injections using a fluorescence stereomicroscope.

For the selection of the correctly injected embryos we performed a double check procedure with two different operators in order to minimize any possible human bias in the embryo selection.

In all experiments, *GLUD2*-injected embryos were compared with embryos injected with the only eGFP capped mRNA at the same developmental stage and cultured in the same conditions (same medium, temperature, same incubator etc.) as a control.

Microinjections were performed using a FemtoJet microinjector (Eppendorf).

### 2.18. Whole-Mount *in situ* hybridization

Zebrafish embryos were manually dechorionated, fixed in 4% paraformaldehyde at the desired developmental stages and stored in methanol at –20 °C. *In situ* hybridization was then performed as previously described [39]. Digoxigenin-UTP labeled antisense RNA probes to detect *pcna*, *gfap*, *slc1a3a*, *slc1a2b* and *cyclin D1* transcripts were generated via *in-vitro* transcription according to the manufacturer's instructions (Roche). The enzymes used for plasmids linearization and polymerases for probes transcription are indicated: *pcna* (*NotI*, T7), *gfap* (*Sall*, SP6), *slc1a3a* (*BamHI*, SP6), *slc1a2b* (*EcoRV*, T7), *cyclin D1* (*SpeI*, T7). The color reaction was carried out using the BM Purple substrate (Roche). After color development, embryos were post-fixed and bleached under light to remove the pigment.

The constructs were kindly provided by Prof. Wolfgang Driever (*cyclin D1*), Prof. Gerald B. Downes (*slc1a2b*), Prof. Yi-Chuan Cheng (*gfap*, *slc1a3a*). *Pcna* construct was generated as described in Baumgart et al., 2014<sup>39</sup>.

### 2.19. Statistical analysis

All results are presented as mean  $\pm$  SD of at least three independent experiments. For qRT-PCR experiments, graphs are representative of three independent experiments with three technical replicates each. Data were statistically analyzed applying student's *t*-test and visualized using GraphPad Prism software (GraphPad Software, La Jolla, CA). Differences were considered statistically significant when  $p < 0.05$  and represented as: \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .

## 3. Results

### 3.1. *GLUD2* expression is associated with GBM prognosis and histopathological classification

#### 3.1.1. RNA-Seq

We previously used whole-transcriptome RNA sequencing [17] to analyze 13 newly diagnosed cases of primary FFPE (formalin-fixed and paraffin-embedded) GBM, specifically selected for different length of recurrence-free survival time (RFS). We defined three groups: the short-term group (S) with RFS  $< 6$  months ( $n = 6$ ), the medium term group (M) with  $16 < \text{RFS} < 23$  months ( $n = 3$ ) and the long-term group (L) with RFS  $> 25$  months ( $n = 4$ ). Here, we performed a functional enrichment analysis of the identified transcripts, finding statistically significant differences in glutamate metabolism genes (Supplementary Table S1). In particular, *GLUD2* mRNA expression means in the two extreme groups, S and L RFS GBM patients, were respectively 10.49 and 143.05 with a fold change of 13.64, and a *p*-value of 0.05 (Fig. 1a). Moreover, immunohistochemical analysis revealed that the protein expression of *GLUD2* detected in long RFS GBM tissues was higher than that in short GBM (Fig. 1b).

#### 3.1.2. Geo dataset analysis


From the GEO dataset we retrieved seventy-seven samples from newly diagnosed cases of high-grade gliomas, which were profiled via microarray analysis, to identify changes in *GLUD2* mRNA expression that relates to both survival and disease progression (Gene Expression Omnibus dataset accession number: GSE4271, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4271>).

We divided patients' cohort into two groups, depending on their clinical outcome: overall survival (OS)  $< 2$  years (OS  $< 103$  weeks) and OS  $> 2$  years (OS  $> 104$  weeks). The longer survival group is defined by higher expression levels of *GLUD2* (Fig. 1c;  $p = 0.0016$ ). Then we associated *GLUD2* expression levels to the World Health Organization (WHO) classification system of glioma grading. *GLUD2* resulted more expressed in grade III glioma tumors, compared to the most aggressive form of glioma, GBM grade IV (Fig. 1d;  $p < 0.0001$ ). Finally, based on the molecular sub-classification of high-grade astrocytoma, reported on the literature [18], we evaluated *GLUD2* expression levels into the proneural, proliferative and mesenchymal classes. Among these three groups, the proneural group, associated with the most favorable outcome, was characterized by higher levels of *GLUD2* (Fig. 1e;  $p < 0.0001$ ).

### 3.2. Two human GBM cell lines with different *GLUD2* expression levels reveal distinct proliferation rate and colony formation capacity

#### 3.2.1. *GLUD2* molecular status in human Gbm cell lines

We selected two GBM human cell lines, T98G and U118, to investigate *GLUD2* expression level and enzyme activity. U118 cells had higher levels of both *GLUD2* mRNA (Supplementary Fig. S1a;  $p = 0.0009$ ) and protein (Supplementary Fig. S1b–c) than T98G cells. Moreover, glutamate dehydrogenase activity, in the direction of oxidative deamination of glutamate, showed higher enzymatic activity in U118 than T98G cells (Supplementary Fig. S1d;  $p < 0.0001$ ). The whole gene *GLUD2* (including promoter region) of both cell lines were sequenced and no mutations were identified. Moreover, mutations in codon 132 of *IDH1* and codons 140 or 172 of *IDH2* have not been identified.



**Fig. 1.** *GLUD2* mRNA expression is related to recurrence free survival, prognosis, and histopathological classification in high-grade glioma patients. (a) *GLUD2* mRNA expression in GBM patients with short RFS ( $< 6$  months) and long RFS ( $> 25$  months) from NGS analysis. (b) Immunohistochemical stain of *GLUD2* protein in GBM patients with short and long RFS. (c) *GLUD2* mRNA expression in GBM patients with long survival ( $> 104$  weeks) and short survival ( $< 103$  weeks) from GSE4271 dataset. (d) *GLUD2* mRNA expression in WHO grade III and WHO grade IV gliomas from GSE4271 dataset. (e) *GLUD2* mRNA expression association with molecular sub classification in high-grade gliomas and relative prognosis from GSE4271 dataset. Data are presented as mean  $\pm$  SD and differences were considered statistically significant when  $p < 0.05$  and represented as: \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .

### 3.2.2. U118 and T98G cell behavior

Once established statistically significant differences in *GLUD2* expression level and enzyme activity, we performed *in-vitro* cell proliferation and tumorigenic assays to investigate U118 and T98G cell behavior dissimilarities.

Cell proliferation rate in T98G at four different time points, T0, T1 (24 h), T2 (48 h) and T3 (72 h), as shown in Supplementary Fig. S1e, was higher than in U118, ( $p = 0.0128$  T1, 0.0003 T2 and 0.0015 T3).

Colony-forming assay revealed a higher colonies number in T98G cells compared to U118 cells (Supplementary Fig. S1f;  $p < 0.0001$ ). Therefore, *GLUD2* lower expression was associated with enhancing cell proliferation signal and higher colony formation ability.

### 3.3. *GLUD2* overexpression decreases proliferation, migration, invasion and colony formation abilities of GBM Cells

#### 3.3.1. *GLUD2* overexpression in human GBM cell lines

We evaluated the effects of *GLUD2* overexpression on T98G cells, selected due to lower *GLUD2* expression. T98G cells were transfected with *GLUD2-IRES-GFP* plasmid system (pIRES-*GLUD2*). As a control, we transfected the same cells with the empty vector (pIRES Vector). After transfection, *GLUD2* mRNA expression (Supplementary Fig. S2a;  $p < 0.0001$ ), *GLUD2* protein expression (Supplementary Fig. S2b-c) and *GLUD2* enzymatic activity (Supplementary Fig. S2d;  $p < 0.0001$ ) were increased in pIRES-*GLUD2* cells compared to cells with empty vector.

#### 3.3.2. Cell functional *in-vitro* studies on *GLUD2* overexpressing T98G cells

We used a WST-1 cell proliferation assay to determine the effect of *GLUD2* overexpression in T98G cells at four different time points, T0, T1 (24 h), T2 (48 h) and T3 (72 h). We found that overexpression of

*GLUD2* inhibits cell proliferation (Fig. 2a;  $p = 0.0018$  T1, 0.0006 T2, 0.0146 T3).


We investigated, by wound healing assay, the effect of *GLUD2* overexpression on migration in T98G cells at three different time points, T0, T1 (24 h), T2 (48 h) and T3 (72 h). The wound healing assay results showed that *GLUD2* overexpression suppressed the wound healing ability compared with empty vector transfected cells (Fig. 2b;  $p = 0.0087$  T1, 0.0213 T2, 0.0058 T3). We then analyzed wound healing assay only looking at the GFP signal, to compare migration capacity of transfected cells in relation to their different *GLUD2* expression levels. We observed that pIRES-*GLUD2* cells were almost unable to move into the wound whereas control cells transfected with vector alone (pIRES Vector) invaded the wound area (Fig. 2c;  $p = 0.0250$ ). To determine the effect of *GLUD2* overexpression on T98G cell invasion, we performed a transwell invasion assay. The number of migrating cells was distinctly lower in pIRES-*GLUD2* cells than in control cells (Fig. 2d;  $p < 0.0001$ ).

Colony formation assays were performed in order to evaluate *GLUD2* overexpression effect on the clonogenic survival. *GLUD2* overexpression reduced the T98G colony formation ability (Fig. 2e;  $p = 0.0045$ ).

### 3.4. *GLUD2* silencing increases proliferation, migration, invasion and colony formation abilities of GBM cells

#### 3.4.1. *GLUD2* silencing in human GBM cell lines

We examined the effects of *GLUD2* silencing selecting U118 cells due to their higher *GLUD2* expression. U118 cells were transfected with *GLUD2* siRNA system (siRNA *GLUD2*). As control, we transfected the same cells with a non-targeting negative control siRNA (siRNA C+). As shown in Supplementary Fig. S1, after transfection with siRNA *GLUD2*, *GLUD2* mRNA expression (Supplementary Fig. S1a;



**Fig. 2.** *GLUD2* overexpression decreases GBM cells proliferation, migration, invasion and colony formation abilities. (a) Cell viability of T98G cells after *GLUD2* overexpression (pIRES-*GLUD2*) and control (pIRES Vector) at the time of seeding (T0) and after 24 h (T1), 48 h (T2) and 72 h (T3). (b) Wound healing assay of T98G cells after *GLUD2* overexpression (pIRES-*GLUD2*) and control (pIRES Vector) and (c) their relative wound invasion ability. (d) Transwell migration assay of T98G cells after *GLUD2* overexpression (pIRES-*GLUD2*) and control (pIRES Vector). Cells that passed through the membrane were counted in five visual fields as migrated cells. (e) Colony formation assay of T98G cells after *GLUD2* overexpression (pIRES-*GLUD2*) and control (pIRES Vector). Colonies were counted in five non-overlapping fields. Data are presented as mean  $\pm$  SD and differences were considered statistically significant when  $p < 0.05$  and represented as: \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .

$p < 0.0001$ ), *GLUD2* protein expression (Supplementary Fig. S1b and c) and *GLUD2* enzymatic activity (Supplementary Fig. S1d;  $p < 0.0001$ ) were decreased compared to control cells.

### 3.4.2. Cell functional in-vitro studies on *GLUD2* silenced U118 cells

We used a WST-1 cell proliferation assay to determine the effect of *GLUD2* silencing in U118 cells. We found that silencing of *GLUD2* enhances cell proliferation (Fig. 3a;  $p < 0.0001$  T1,  $p < 0.0001$  T2,  $p = 0.0002$  T3).


We investigated the effect of *GLUD2* silencing on migration in U118 cells by wound healing at three different time points, T0, T1 (24 h), T2 (48 h) and T3 (72 h). The wound healing assay results showed that *GLUD2* silencing improved the wound healing ability compared to control siRNA transfected cells (Fig. 3b;  $p = 0.0010$  T1, 0.0272 T2,

0.0015 T3). To determine the effect of *GLUD2* silencing on U118 cell invasion, we performed a transwell invasion assay. The number of migrating cells was distinctly higher in siRNA *GLUD2* cells than in control cells (Fig. 3c;  $p < 0.0001$ ).


Colony formation assays were performed in order to evaluate *GLUD2* silencing effect on the clonogenic survival. *GLUD2* silencing increased the U118 colony formation ability (Fig. 3d;  $p < 0.0001$ ).

### 3.5. *GLUD2* expression levels influence G1/S transition regulating cyclins D1 and E in human GBM cells

We studied by flow cytometry the effect of both *GLUD2* overexpression and silencing on T98G and U118 cell cycle. *GLUD2* overexpression in T98G cells showed a significant increase in G0/G1 phase and a



**Fig. 3.** *GLUD2* silencing increases GBM cells proliferation, migration, invasion and colony formation abilities. (a) Cell viability of U118 cells after *GLUD2* silencing (siRNA *GLUD2*) and control (siRNA C+) at the time of seeding (T0) and after 24 h (T1), 48 h (T2) and 72 h (T3). (b) Wound healing assay of U118 cells after *GLUD2* silencing (siRNA *GLUD2*) and control (siRNA C+). (c) Transwell migration assay of U118 cells after *GLUD2* silencing (siRNA *GLUD2*) and control (siRNA C+). Cells that passed through the membrane were counted in five visual fields as migrated cells. (d) Colony formation assay of U118 cells after *GLUD2* silencing (siRNA *GLUD2*) and control (siRNA C+). Colonies were counted in five non-overlapping fields. Data are presented as mean  $\pm$  SD and differences were considered statistically significant when  $p < 0.05$  and represented as: \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .



**Fig. 4.** *GLUD2* overexpression and silencing in GBM cells modulate the expression of *cyclin D1* and *cyclin E*, influencing cell cycle phases and affect mitochondrial function and ROS production. (a) Cell cycle distribution in T98G *GLUD2* overexpressed cells (pIRES-GLUD2) and U118 *GLUD2* silenced cells (siRNA *GLUD2*) compared to relative control cells. (b) *Cyclin D1* and *Cyclin E* mRNA expression in *GLUD2* overexpressed cells (pIRES-GLUD2) and *GLUD2* silenced cells (siRNA *GLUD2*) compared to relative control cells. (c) Oxygen consumption rate (OCR) of T98G control cells (pIRES Vector), T98G *GLUD2* overexpressed cells (pIRES-GLUD2), U118 control cells (siRNA C+) and U118 *GLUD2* silenced cells (siRNA *GLUD2*) in Seahorse XFp Cell Mito Stress Test. (d) Basal and maximal respiration, non-mitochondrial respiration, H<sup>+</sup> (Proton) leak, ATP-linked respiration, spare respiratory capacity and coupling using modulators of cellular respiration. (e) ROS levels of T98G *GLUD2* overexpressed cells (pIRES-GLUD2), U118 *GLUD2* silenced cells (siRNA *GLUD2*) and relative controls quantified by measuring the fluorescence at an excitation/emission wavelength of 485/535 after CellROX Green probe incubation. Data are presented as mean  $\pm$  SD and differences were considered statistically significant when  $p < 0.05$ ,  $**p < 0.01$  and  $***p < 0.001$ . (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

statistically significant decrease in S and G2/M phases when compared to control cells (Fig. 4a;  $p < 0.0001$  G0/G1 and  $p = 0.0008$  S). *GLUD2* silencing in U118 cells with siRNA did not lead to a statistically significant change in the cell cycle (Fig. 4a).

We then evaluated the mRNA expression of G1 phase cell cycle regulators, *cyclin D1* and *cyclin E*. *GLUD2* overexpression in T98G cells is characterized by *cyclin D1* and *cyclin E* downregulation (Fig. 4b;  $p = 0.0083$  D1 and  $p = 0.0003$  E). *GLUD2* silencing in U118 cells showed an overexpression of both *cyclin D1* and *cyclin E* (Fig. 4b;  $p = 0.0124$  D1 and  $p = 0.0336$  E).

### 3.6. Changes in *GLUD2* expression levels determine alterations of mitochondrial functions in human GBM cells


To obtain insight into mitochondria functional differences between *GLUD2* overexpressed and silenced cells, we analyzed mitochondrial function and metabolic phenotype by quantifying oxygen consumption rate (OCR) with Seahorse XFp extracellular flux analyzer.

We examined *GLUD2* overexpression and silencing effects on basal respiration, ATP-linked respiration, H<sup>+</sup> (Proton) leak, maximal respiration, spare respiratory capacity, and non-mitochondrial respiration, using the Seahorse XFp Cell Mito Stress Test (Supplementary Fig. S3). *GLUD2* overexpression in T98G cells led to a statistically significant increase in the basal levels of mitochondrial respiration ( $p$

$= 0.0015$ ) and maximal respiration ( $p < 0.0001$ ) compared to empty vector control (Fig. 4c–d). Instead, *GLUD2* silencing in U118 caused a statistically significant reduction of basal mitochondrial respiration ( $p = 0.0416$ ), whereas no statistically significant differences were observed in the maximal respiration compared to the respective control (Fig. 4c–d). Non-mitochondrial respiration was also statistically increased in T98G cells with *GLUD2* overexpression ( $p = 0.0004$ ) and decreased in U118 cells with *GLUD2* silencing ( $p = 0.0057$ ) compared to respective controls (Fig. 4c–d). Despite proton leak and ATP production were increased in T98G cells with *GLUD2* overexpression and decreased in U118 cells with *GLUD2* silencing, compared to the respective controls, differences were not statistically significant (Fig. 4c–d). Spare respiratory capacity was significantly increased in *GLUD2* overexpressed T98G cells ( $p = 0.0006$ ) whereas no significant differences were observed in the spare respiratory capacity in *GLUD2* silenced U118 cells. No statistically significant differences, in couple efficiency, were observed in both *GLUD2* overexpressed T98G cells and *GLUD2* silenced U118 cells compared to their respective controls (Fig. 4c–d).

To evaluate reactive oxygen species (ROS) levels, *GLUD2* overexpressed cells, *GLUD2* silenced cells and relative controls were stained with CellROX Green reagent, followed by fluorescence quantification of oxidative stress. We found higher levels of ROS in the *GLUD2* overexpressed cells ( $p < 0.0001$ ) and lower levels in the *GLUD2* silenced cells ( $p < 0.0001$ ) compared to controls (Fig. 4e).





**Fig. 5.** *GLUD2* overexpression affects cell proliferation in zebrafish embryos. (a) Schematic mRNA microinjection procedure into the yolk sac of a one-cell stage zebrafish embryo. (b) Zebrafish embryo injected with *eGFP* mRNA at 24 hpf. (c) Control immunohistochemical staining of *GLUD2* protein on 24 hpf zebrafish embryos injected with *eGFP* mRNA (control) or *GLUD2* and *eGFP* mRNAs (*GLUD2*), showing *GLUD2* expression in *GLUD2*-injected embryos. (d) Immunohistochemical staining of pH 3 (phosphohistone H3) on 24 and 48 hpf embryos injected with only *eGFP* or *eGFP* and *GLUD2* mRNAs. (e) Number of pH 3-positive cells was counted in the hindbrain area (black square in d) of 48 hpf embryos; n, total number of analyzed embryos, N, number of independent experiments. (f) Whole mount *in situ* hybridization on both *GLUD2*-injected and control embryos at 48 and 72 hpf, showing a reduction of *pcna* expression in *GLUD2*-injected embryos; arrowheads indicate the proliferative region of the optic tectum. 72 hpf embryos are shown in dorsal and lateral view. (g) Percentage of *GLUD2*-injected and control embryos with reduced *pcna* expression; n, total number of analyzed embryos, N, number of independent experiments. (h) qRT-PCR analysis of *pcna* expression in *GLUD2*-injected and control embryos at 48 and 72 hpf, showing a reduction of *pcna* expression in *GLUD2*-injected embryos compared to controls; arrowheads indicate the proliferative region of the optic tectum. 48 hpf embryos are shown in dorsal and lateral view. (i) Whole mount *in situ* hybridization on 48 hpf embryos, showing a reduced *cyclin D1* expression in *GLUD2*-injected embryos compared to controls; arrowheads indicate the proliferative region of the optic tectum. 48 hpf embryos are shown in dorsal and lateral view. (j) Percentage of *GLUD2*-injected and control embryos with reduced *cyclin D1* expression; n, total number of analyzed embryos, N, number of independent experiments. (k) qRT-PCR analysis of *cyclin D1* expression level in control and *GLUD2*-injected embryos; n, total number of analyzed embryos, N, number of independent experiments. Data are presented as mean  $\pm$  SD and differences were considered statistically significant when  $p < 0.05$  and represented as: \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .

### 3.7. *GLUD2* overexpression in zebrafish embryos

The *GLUD2* overexpression ability to reduce the proliferation rate of GBM cell line T98G well correlates with the *GLUD2* higher expression in the long RFS group of patients. Nevertheless, the tissue culture condition could not entirely recapitulate the *in-vivo* condition in which multiple signaling factors and cell-cell interactions could influence cell behavior and metabolism. We therefore decided to test the function of *GLUD2* in an *in-vivo* system to verify the *GLUD2* overexpression influence on cell proliferation in the central nervous system. We chose *Danio rerio* (zebrafish) as experimental model as it is a well accepted tool in biomedical research, including brain cancer research [19,20], allowing us to overexpress the human *GLUD2* and to evaluate its effect on neurons and glial cells behavior in the developing brain.

Embryos were injected with *GLUD2* and *eGFP* mRNAs at one-cell stage (Fig. 5a). As a control, a group of embryos was injected with only *eGFP* mRNA. Effectively injected embryos were selected detecting *eGFP* expression by fluorescence stereomicroscope (Fig. 5b).

We first assessed the ability of zebrafish embryos to express the human *GLUD2* protein; *GLUD2* expression was observed in *GLUD2*-injected embryos by immunohistochemistry, but not in the control group (Fig. 5c).

#### 3.7.1. *GLUD2* overexpression affects cell proliferation in zebrafish embryos

We used a phosphohistone H3 antibody to analyze cell proliferation in the central nervous system and, in particular, to visualize cells during M phase of the cell cycle in zebrafish embryos at two different developmental stages, 24 hpf (hours post fertilization) and 48 hpf (Fig. 5d). The result revealed a decreased number of proliferating cells in *GLUD2*-injected embryos compared to controls. This observation was confirmed


by counting phosphohistone H3-positive cells in the hindbrain area of embryos at 48 hpf (Fig. 5e).

We then performed a whole mount *in situ* hybridization (WISH) using an antisense RNA probe to detect *pcna* (proliferating cell nuclear antigen) mRNA, which encodes a non-histone nuclear protein used as a marker for cells in S phase. At 48 hpf, *GLUD2*-injected embryos showed reduced *pcna* transcript expression level compared to controls, that was confirmed by quantitative real-time RT-PCR (qRT-PCR) (Fig. 5f–h). At later stages, 72 hpf, the effect became more pronounced highlighting a severely reduced *pcna* gene expression clearly detectable in proliferative regions of the optic tectum of *GLUD2*-injected embryos (Fig. 5f, g). These results suggested that *GLUD2* overexpression could cause a reduction of cells in both S and M phases confirming the results obtained in T98G cells.

As in GBM cell line T98G overexpressing *GLUD2* the reduced proliferation correlates with a reduction of *cyclin D1* expression, we evaluated *cyclin D1* mRNA level in *GLUD2* overexpressing embryos both by *in situ* hybridization and qRT-PCR (Fig. 5i–k). *Cyclin D1* WISH signal intensity was strongly decreased in the tectal proliferative region of 48 hpf *GLUD2*-injected embryos in comparison to controls (Fig. 5i, j) and was found to be significantly downregulated in *GLUD2*-injected embryos also by qRT-PCR analysis (Fig. 5k).

#### 3.7.2. *GLUD2* overexpression impairs glial cells formation without affecting neurons development

An altered glutamate metabolism could affect not only glial cells expressing *GLUD2* but also the nearby neurons survival. Zebrafish model allowed us to further investigate the effects of *GLUD2* overexpression on neural and glial development. We first questioned whether this enzyme might have an influence on zebrafish gliogenesis. We therefore assessed the expression pattern of different glial markers by WISH on



**Fig. 6.** *GLUD2* overexpression impairs glial cells formation, without affecting neurons development in zebrafish embryos. (a) Whole mount *in situ* hybridization on 48 hpf embryos, indicating a reduction of the expression of three different glial cell markers (*slc1a3a*, *slc1a2b* and *gfap*) in *GLUD2*-injected embryos compared to controls. (b) Percentage of *GLUD2*-injected and control embryos with decreased glial cell marker expression; n, total number of analyzed embryos, N, number of independent experiments. (c) qRT-PCR analysis confirming the reduced transcript level of *gfap* in *GLUD2*-injected embryos relative to control embryos; n, total number of analyzed embryos, N, number of independent experiments. (d) Immunohistochemical staining of HuD on 48 hpf embryos shown in dorsal and lateral view (n = 84 for control embryos and n = 92 for *GLUD2*-injected embryos subdivided in three independent experiments) revealing no visible differences in the expression of this postmitotic neuronal marker between *GLUD2*-injected and control embryos. Data are presented as mean  $\pm$  SD and differences were considered statistically significant when  $p < 0.05$  and represented as: \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .

48 hpf embryos. Overexpression of *GLUD2* mRNA caused a WISH signal reduction of *slc1a3a* (Fig. 6a, b), an early glial marker encoding an excitatory amino acid transporter (EAAT) expressed at glutamatergic synapses [21]. In addition, we analyzed the expression of *slc1a2b* (Fig. 6a, b), an EAAT mainly present in a subset of glial cells [22], which was found decreased in *GLUD2*-injected embryos compared to controls. To further evaluate whether the reduction of *slc1a3a* was due to increased glial differentiation or not, we examined the expression of a mature glial cells marker, *gfap*, also used as an astrocytes marker [21]. *Gfap* downregulation after *GLUD2* mRNA injection was detected by WISH (Fig. 6a, b) and confirmed by qRT-PCR (Fig. 6c), suggesting an impairment of gliogenesis caused by *GLUD2* overexpression.

With the aim of investigating a potential effect of *GLUD2* overexpression on neurogenesis, we performed an immunohistochemical analysis visualizing the postmitotic neuronal marker HuD distribution (Fig. 6d). Compared to controls, *GLUD2*-injected embryos didn't display visible alterations of HuD expression pattern at 48 hpf, indicating that *GLUD2* overexpression could affect glial cell development without impairing neuronal differentiation and survival.

#### 4. Discussion

Glutamate dehydrogenase (GDH) is a mitochondrial enzyme that catalyzes the reversible inter-conversion of glutamate to  $\alpha$ -KG by using NADP and/or NAD as cofactors. GDH in human exists in *GLUD1* and *GLUD2* gene-encoded isoforms (hGDH1 and hGDH2, respectively). *GLUD1* gene is located on 10q and is expressed widely, whereas *GLUD2* is an intronless gene located on the X chromosome with expression specificity for nervous and testicular tissues [23,24]. In the brain, *GLUD2* expression is mainly associated with astrocytes [24,25] with a substantial mitochondrial localization, representing up to 10% of the matrix protein [10,25,26]. *GLUD2* contributes to important cellular processes, such as the Krebs cycle, ammonia homeostasis and energy production [10,15,24,26,27]; however, its role in cell biology is still incompletely understood [26]. *GLUD2* has the ability to act on both directions of the reaction depending on the availability of the substrate, but in the cancer it is thought that it works mainly in the direction of the oxidative deamination of glutamate and  $\alpha$ -KG production [28].

*GLUD2* initially emerged from our previous NGS analysis [17] conducted on 13 GBM samples from patients with different recurrence time (RFS). *GLUD2* was overexpressed in the tumors of patients with long RFS. We then interrogated the Gene Expression Omnibus dataset in which 77 samples from newly diagnosed cases of high-grade gliomas were profiled via microarray analysis. We found that *GLUD2* overexpression was significantly associated with increased overall survival and lower glioma grading.

We then performed *in-vitro* functional studies on human GBM cells evaluating cellular effect due to changes in *GLUD2* expression levels. In particular, we overexpressed and silenced *GLUD2* in two different cell lines, T98G and U118, respectively. *GLUD2* overexpression led to a significant decrease in cell proliferation, invasion and migration capacity and colony formation ability; at the same time, *GLUD2* silencing caused a statistically significant increase in tumor aggressiveness and tumorigenicity.

There is increasing evidence that glutamate oxidative deamination is the predominant pathway for  $\alpha$ -KG production and therefore its abundance strictly depends on *GLUD2* activity [16,29]. This also suggests another possible explanation of decrease of proliferation following an increase in the enzymatic activity of *GLUD2* and *vice versa*. In fact, when there is higher consumption of glutamate as a substrate, there is higher attraction of glutamate from the outside towards the inside of the cell and as a consequence, the extracellular glutamate decreases with less effect on the promotion of cell proliferation through the activation of its receptors [30]. Other studies have observed that the increase of glutamate uptake within the glioma cell, through the

functional increase of its transporters, decreases tumor proliferation [30,31].

Afterward, we investigated how *GLUD2* expression levels could affect the cell cycle phases and their regulation by checkpoints. Both *cyclin D1* and *cyclin E* expression levels are reduced after *GLUD2* overexpression and this is reflected on the G0/G1 phase increase and S and G2/M phase reduction. However, a variation of cell cycle phases is not appreciable in *GLUD2* silenced cells, although there is a significant increase in both *cyclin D1* and *cyclin E* expression levels. This is probably due to the small difference in the increase of *cyclin E* in *GLUD2* silenced cells compared to control cells. The role of cyclin D1, in fact, is to advance the G1 phase and prepare cells for the S phase; whereas cyclin E is responsible for G1-to-S-phase transition [32].

We also evaluated the consequences of *GLUD2* expression levels variation on mitochondrial function and metabolic phenotype, by measuring oxygen consumption rate (OCR) after *GLUD2* overexpression and silencing. Statistically significant effects, in both overexpression and silencing of *GLUD2* with opposite trends, were observed in the baseline oxygen consumption and non-mitochondrial respiration. *GLUD2* overexpression seems, therefore, correlated with an increase in oxygen consumption, which however does not translate into an increase in oxidative phosphorylation, as there are no significant differences in the production of ATP. The fact that there are differences in non-mitochondrial respiration has led us to investigate the production of reactive oxygen species (ROS). We have indeed observed that *GLUD2* overexpression increased the production of ROS and on the other hand, after *GLUD2* silencing, the production of ROS was decreased, as expected. The effect of *GLUD2* on ROS production, depending on its expression level, helped clarifying the mechanisms by which altered levels of *GLUD2* expression can modify tumor progression and development.

The correlation between *GLUD2* expression levels and ROS production has already been described in the literature [27]. In particular, it has been demonstrated that increased glutamate oxidation by an enhanced *GLUD2* activation by the Ala445 variant in the regulatory domain, may improperly boost mitochondrial oxidative metabolism with consequent increased ROS production [25]. This suggests that a significant gain in *GLUD2* activity can cause severe mitochondrial dysfunction, as mitochondria fail to manage the large amounts of *GLUD2* produced  $\alpha$ -KG. Moreover, it has also been described that *GLUD2* NADPH generation affects ROS homeostasis through NADPH oxidase activation and ROS production [28]. Furthermore, an increase in ROS generation following *GLUD2* overexpression may also explain the resulting cell cycle block in G0 / G1, since it has been shown that increased levels of ROS lead to a decrease in cyclin D1/E expression and promote cell-cycle arrest [33,34].

All these metabolic variations observed *in-vitro* could be differentially regulated *in-vivo* by extracellular stimuli and cell-cell interactions that give rise to a complex and integrated modulation of cell behavior. In order to test the possible effect of *GLUD2* overexpression *in-vivo* we took advantage of zebrafish embryos in which we can easily alter *GLUD2* expression and monitor cell cycle progression in the developing central nervous system. Over the past years, zebrafish has become an effective and alternative tool to the classical mouse model for studying many human diseases including CNS pediatric to adult tumors [19,20]. However obvious evolutive divergences between fishes and humans have always to be taken into account. In this work we decided to use the zebrafish embryo just to evaluate *GLUD2* gene function in a cellular context in which all the metabolic pathways are active and the interaction and exchanges between glia, neurons, hormones, neurotransmitters and metabolites are orchestrated in a complex and dynamic environment that is not reproducible *in-vitro*.

In *GLUD2*-overexpressing embryos we observed a reduced number of mitotic cells in the developing brain that correlated with a decreased level of *cyclin D1* expression mirroring the data obtained in the T98G human GBM cell line. These observations strongly corroborated the *in-vitro* data adding important hints on the possible side effects of the

GLUD2 modulation. The *in-vivo* system, in fact, allowed us to verify how glial cells overexpressing *GLUD2* proceed in their developmental program and how they can influence the behavior of the surrounding neurons. In *GLUD2* overexpressing embryos we observed a failure in the generation of differentiated glial cells, probably due to a block of proliferation of gliogenic precursors, but interestingly neurogenic precursors seem not to be affected as post mitotic neurons developed normally. This aspect could reflect the different metabolic activity of glial cells and neurons and could be of great interest in a therapeutic perspective. The possibility to enhance *GLUD2* activity in GBM could result in a blocked/reduced proliferation of glial cells without affecting the survival of the surrounding neurons.

To the best of our knowledge, this is the first work where *GLUD2* is considered as a key player in GBM progression. These observations may provide a new target for therapeutic interventions in GBM to reduce tumor progression and aggressiveness. On this, however, there is still much to learn about when and how to manipulate glutamate metabolic system as a target and to further clarify the intracellular signaling pathways associated with pathological states. In particular, preclinical studies on more complex animal models than zebrafish, such as murine, will be necessary. This work could represent a starting point to deepen the role of *GLUD2* in GBM *in-vivo* and to design and test possible pharmacological treatments. *GLUD2* enzymatic activity could be increased through the induction of an activating mutation, for example the Ala445 variant in the regulatory domain [25], with a highly advanced genome editing system such as CRISPR/Cas9. Alternatively, activation of *GLUD2* could be achieved by allosteric effectors, such as leucine [35], although in this case the assessment of specificity is extremely important.

#### Author contributions

SF, DC, MO and CMM designed the project and experimental work. SF and PA analyzed the data from RNA-seq and microarray analysis. SF performed the cell culture experiments with additional help from FL, ET, CS and PC. MM supervised histological analysis. FP and AGN gave clinical support. DC performed the zebrafish experiments. SF and DC wrote the manuscript. MO and CMM contributed to data review and interpretation. All authors commented and reviewed the manuscript.

#### Declaration of interests

The authors declare no competing interests.

#### Acknowledgements/funding

None. No funding to declare.

#### Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ebiom.2018.10.008>.

#### References

- Alfardus H, McIntyre A, Smith S. MicroRNA regulation of glycolytic metabolism in glioblastoma. *Biomed Res Int* 2017;2017:9157370.
- Abbruzzese C, Matteoni S, Signore M, et al. Drug repurposing for the treatment of glioblastoma multiforme. *J Exp Clin Cancer Res* 2017;36(1):169.
- Stoyanov GS, Dzhenkov D, Ghenev P, Iliev B, Enchev Y, Tonchev AB. Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. *Med Oncol* 2018;35(3):27.
- Bayin NS, Frenster JD, Sen R, et al. Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. *Oncotarget* 2017;8(39):64932–53.
- Szopa W, Burley TA, Kramer-Marek G, Kaspera W. Diagnostic and therapeutic biomarkers in glioblastoma: current status and future perspectives. *Biomed Res Int* 2017;2017:8013575.
- Yan H, Romero-Lopez M, Benitez LI, et al. 3D mathematical modeling of glioblastoma suggests that transdifferentiated vascular endothelial cells mediate resistance to current standard-of-care therapy. *Cancer Res* 2017;77(15):4171–84.
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005;352(10):987–96.
- Anjum K, Shagufta BI, Abbas SQ, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review. *Biomed Pharmacother* 2017;92:681–9.
- Torok JA, Wegner RE, Mintz AH, Heron DE, Burton SA. Re-irradiation with radiosurgery for recurrent glioblastoma multiforme. *Technol Cancer Res Treat* 2011;10(3):253–8.
- Comelli M, Pretis I, Buso A, Mavelli I. Mitochondrial energy metabolism and signaling in human glioblastoma cell lines with different PTEN gene status. *J Bioenerg Biomembr* 2017;50(1):33–52.
- Libby CJ, Tran AN, Scott SE, Griguer C, Hjelmeland AB. The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells. *Biochim Biophys Acta* 2018;1869(2):175–88.
- Liu G, Zhu J, Yu M, et al. Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients. *J Transl Med* 2015;13:144.
- Maus A, Peters GJ. Glutamate and alpha-ketoglutarate: key players in glioma metabolism. *Amino Acids* 2017;49(1):21–32.
- Danbolt NC, Furness DN, Zhou Y. Neuronal vs glial glutamate uptake: resolving the conundrum. *Neurochem Int* 2016;98:29–45.
- Plaitakis A, Latsoudis H, Spanaki C. The human *GLUD2* glutamate dehydrogenase and its regulation in health and disease. *Neurochem Int* 2011;59(4):495–509.
- Plaitakis A, Kalef-Ezra E, Kotzamani D, Zaganas I, Spanaki C. The glutamate dehydrogenase pathway and its roles in cell and tissue biology in health and disease. *Biology (Basel)* 2017;6(1).
- Franceschi S, Lessi F, Aretini P, et al. Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer players. *Oncotarget* 2018;9(35):24014–27.
- Phillips HS, Kharbada S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 2006;9(3):157–73.
- Corallo D, Candiani S, Ori M, Aveic S, Tonini GP. The zebrafish as a model for studying neuroblastoma. *Cancer Cell Int* 2016;16:82.
- Idilli AI, Precazzino F, Mione MC, Anelli V. Zebrafish in translational cancer research: insight into leukemia, melanoma, glioma and endocrine tumor biology. *Genes (Basel)* 2017;8(9).
- Cheng YC, Chiang MC, Shih HY, et al. The transcription factor hairy/E(spl)-related 2 induces proliferation of neural progenitors and regulates neurogenesis and gliogenesis. *Dev Biol* 2015;397(1):116–28.
- McKeown KA, Moreno R, Hall VL, Ribera AB, Downes GB. Disruption of *Eaat2b*, a glutamate transporter, results in abnormal motor behaviors in developing zebrafish. *Dev Biol* 2012;362(2):162–71.
- Kanavouras K, Mastorodemos V, Borompokas N, Spanaki C, Plaitakis A. Properties and molecular evolution of human *GLUD2* (neural and testicular tissue-specific) glutamate dehydrogenase. *J Neurosci Res* 2007;85(15):3398–406.
- Spanaki C, Kotzamani D, Plaitakis A. Widening spectrum of cellular and subcellular expression of human *GLUD1* and *GLUD2* glutamate dehydrogenases suggests novel functions. *Neurochem Res* 2017;42(1):92–107.
- Shashidharan P, Plaitakis A. The discovery of human *GLUD2* glutamate dehydrogenase and its implications for cell function in health and disease. *Neurochem Res* 2014;39(3):460–70.
- Zaganas I, Kanavouras K, Mastorodemos V, Latsoudis H, Spanaki C, Plaitakis A. The human *GLUD2* glutamate dehydrogenase: localization and functional aspects. *Neurochem Int* 2009;55(1–3):52–63.
- Tarasenko VI, Garnik EY, Shmakov VN, Konstantinov YM. Induction of Arabidopsis *gdh2* gene expression during changes in redox state of the mitochondrial respiratory chain. *Biochemistry (Mosc)* 2009;74(1):47–53.
- Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. *Nat Rev Cancer* 2016;16(11):749.
- Schousboe A, Scafidi S, Bak LK, Waagepetersen HS, McKenna MC. Glutamate metabolism in the brain focusing on astrocytes. *Adv Neurobiol* 2014;11:13–30.
- Vanhoutte N, Hermans E. Glutamate-induced glioma cell proliferation is prevented by functional expression of the glutamate transporter GLT-1. *FEBS Lett* 2008;582(13):1847–52.
- de Groot J, Sontheimer H. Glutamate and the biology of gliomas. *Glia* 2011;59(8):1181–9.
- Pucci B, Kasten M, Giordano A. Cell cycle and apoptosis. *Neoplasia* 2000;2(4):291–9.
- Li C, Peng W, Song X, Wang Q, Wang W. Anticancer effect of icaritin inhibits cell growth of colon cancer through reactive oxygen species, Bcl-2 and cyclin D1/E signaling. *Oncol Lett* 2016;12(5):3537–42.
- Wang X, Liu J, Jiang L, et al. Bcl1 induces endothelial cell apoptosis and cell-cycle arrest through ROS generation. *Oxidative Med Cell Longev* 2016;2016:6234043.
- Anno T, Uehara S, Katagiri H, et al. Overexpression of constitutively activated glutamate dehydrogenase induces insulin secretion through enhanced glutamate oxidation. *Am J Physiol Endocrinol Metab* 2004;286(2):E280–5.
- Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 2012;9(7):671–5.
- Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. *Dev Dyn* 1995;203(3):253–310.
- Busquet F, Strecker R, Rawlings JM, et al. OECD validation study to assess intra- and inter-laboratory reproducibility of the zebrafish embryo toxicity test for acute aquatic toxicity testing. *Regul Toxicol Pharmacol* 2014;69(3):496–511.
- Baumgart M, Groth M, Priebe S, et al. RNA-seq of the aging brain in the short-lived fish *N. furzeri* – conserved pathways and novel genes associated with neurogenesis. *Aging Cell* 2014;13(6):965–74.